Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma.
We describe a patient in whom synchronous breast cancer and small-cell lung cancer, and metachronous renal cell carcinoma were diagnosed within an 11 months period. All three tumors were treated surgically, followed by administration of tamoxifen, adjuvant chemotherapy with etoposide (2.8 g/m2 total) and vindesine, and administration of interferon alpha and flutamide. The patient developed acute myelomonocytic leukemia 26 months after discontinuation of etoposide-containing chemotherapy. This pattern of multiple neoplasms fits the wider disease spectrum associated with germline mutations of the p53 gene; however, analysis of p53 exons 5-8 did not disclose any sequence abnormalities in this patient. In conclusion, clustering of four (synchronous and metachronous) malignancies may on rare occasions occur in an individual patient and in the absence of a family history of cancer; the sequence during which treatment of primary malignancies may result in treatment-related acute myelocytic leukemia is discussed.
Pötzsch
C
C
Department of Hematology/Oncology, University of Freiburg Medical Center, Germany.
Fetscher
S
S
Mertelsmann
R
R
Lübbert
M
M
D001943:Breast Neoplasms / Q000175:diagnosis*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis*; D018288:Carcinoma, Small Cell / Q000175:diagnosis; D005260:Female; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis*; D015479:Leukemia, Myelomonocytic, Acute / Q000175:diagnosis* / Q000235:genetics; D008175:Lung Neoplasms / Q000175:diagnosis*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis; D018807:Polymorphism, Single-Stranded Conformational